

EXHIBIT A

**THE CLAIMS WHICH WILL BE PENDING
UPON ENTRY OF THE INSTANT AMENDMENT
(filed April 19, 2002)
U.S. PATENT APPLICATION SERIAL NO. 09/724,419**

23. An embryonated egg containing a recombinantly engineered negative strand RNA virus which has been engineered to encode an epitope derived from another virus, wherein the embryonated egg is less than ten days old.

24. An immature embryonated egg containing a reassorted segment negative strand RNA virus, wherein at least one of the segments is derived from a different virus and the embryonated egg is less than ten days old.

25. An immature embryonated egg containing an attenuated influenza virus recombinantly engineered to encode an epitope from a different virus, wherein the embryonated egg is less than ten days old with the proviso that said virus is not influenza C.

26. The immature embryonated egg of Claim 25, wherein the attenuated influenza virus has one or more modifications in the NS1 gene which diminishes or eliminates the ability of the NS1 gene product to antagonize the cellular interferon response.

27. The immature embryonated egg of Claim 23, 24, or 25, wherein the egg is a six to nine days old chick egg.

28. The immature embryonated egg of Claim 23, wherein the negative RNA virus is influenza A virus, influenza B virus, respiratory syncytial virus, parainfluenza virus, mumps virus, measles virus, Newcastle disease virus, or vesicular stomatitis virus.

29. The immature embryonated egg of Claim 23 or 24, wherein the negative strand RNA virus is influenza A or B virus.

30. An interferon deficient substrate containing an attenuated negative strand RNA virus, wherein the interferon deficient substrate is an embryonated egg less than 10 days old or an interferon deficient cell line with the proviso that said virus is not influenza C virus and the interferon deficient substrate is not Vero cells and is not Stat1 (-) cell lines.

31. The interferon deficient substrate of Claim 30, wherein the attenuated negative strand RNA virus is an attenuated influenza virus.

32. The interferon deficient substrate of Claim 31, wherein the influenza virus has one or more modifications in the NS1 gene which diminishes or eliminates the ability of the NS1 gene product to antagonize the cellular interferon response.

33. The interferon deficient substrate of Claim 30, wherein the negative strand RNA virus is influenza A virus, influenza B virus, respiratory syncytial virus, parainfluenza virus, mumps virus, measles virus, Newcastle disease virus, or vesicular stomatitis virus.

34. The interferon deficient substrate of Claim 30 or 32, wherein the egg is a six to nine days old chick egg.

35. The interferon deficient substrate of Claim 30, wherein the attenuated negative strand RNA virus is engineered to encode an epitope derived from another virus.

36. The interferon deficient substrate of Claim 30, wherein the attenuated negative strand RNA virus has a segmented genome comprising at least one segment derived from a different virus.

37. An interferon deficient substrate containing de1NS1 or NS1-99, wherein the interferon deficient substrate is not Vero cells.

38. The interferon deficient substrate of Claim 37, wherein the interferon deficient substrate is an immature embryonated egg.

39. The interferon deficient substrate of Claim 38, wherein the immature embryonated egg is a chick egg less than ten days old.

40. The interferon deficient substrate of Claim 39, wherein the immature embryonated egg is a chick egg six to nine days old.